Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2009

01-02-2009 | Review

Patho-biological aspects of basal-like breast cancer

Authors: Emad A. Rakha, Maysa E. El-Sayed, Jorge Reis-Filho, Ian O. Ellis

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Abstract

Breast cancer comprises a remarkably diverse group of diseases in terms of presentation, morphology, molecular profile and response to therapy. Recent gene expression profiling of breast cancer has identified specific molecular subtypes of clinical significance. Basal-like cancers (BLC) comprise a group of tumours that are characterised by an expression signature similar to that of the basal/myoepithelial cells of the breast and cluster together with BRCA1 associated tumours. Although BLC has fascinated oncologists and scientists alike due to its enigmatic clinical and pathological parameters, there is no consensus about the definition and method of identification in routine practice of this rather heterogeneous group of cancers. Furthermore, the prognostic significance of BLCs and response to specific chemotherapy regimens are still a matter debate. In this review, we discuss the molecular and morphological features, prognostic significance of BLC, and explore its impact on the concept of the breast cancer stem cell.
Literature
1.
Beckmann MW et al (1997) Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 75(6):429–439PubMed
2.
Perou CM et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMed
3.
Sorlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874PubMed
4.
Sorlie T et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418–8423PubMed
5.
Bertucci F et al (2000) Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 9(20):2981–2991PubMed
6.
Bergamaschi A et al (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45(11):1033–1040PubMed
7.
Chin K et al (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10(6):529–541PubMed
8.
Neve RM et al (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515–527PubMed
9.
Zhao H et al (2004) Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15(6):2523–2536PubMed
10.
Sotiriou C et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262–272PubMedCrossRef
11.
Sotiriou C et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100(18):10393–10398PubMed
12.
Dairkee SH et al (1987) Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease. Breast Cancer Res Treat 10(1):11–20PubMed
13.
Santini D et al (1996) Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J Pathol 179(4):386–391PubMed
14.
Savage K et al (2007) Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res 13(1):90–101PubMed
15.
Yehiely F et al (2006) Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12(11):537–544PubMed
16.
Hu Z et al (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96PubMed
17.
Wilhelmsen K, Litjens SH, Sonnenberg A (2006) Multiple functions of the integrin alpha6beta4 in epidermal homeostasis and tumorigenesis. Mol Cell Biol 26(8):2877–2886PubMed
18.
Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10(8):789–799PubMed
19.
Koshikawa N et al (2000) Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 148(3):615–624PubMed
20.
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70PubMed
21.
Dumont N, Arteaga CL (2003) Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 3(6):531–536PubMed
22.
Molkentin JD (2000) The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 275(50):38949–38952PubMed
23.
Fan C et al (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355(6):560–569PubMed
24.
Paik S et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826PubMed
25.
van de Vijver MJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009PubMed
26.
Chang HY et al (2005) Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 102(10):3738–3743PubMed
27.
Ma XJ et al (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5(6):607–616PubMed
28.
Dai H et al (2005) A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 65(10):4059–4066PubMed
29.
Ivshina AV et al (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66(21):10292–10301PubMed
30.
Stingl J et al (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439(7079):993–997PubMed
31.
Nielsen TO et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374PubMed
32.
Harris LN et al (2007) Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13(4):1198–1207PubMed
33.
Jumppanen M et al (2007) Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9(1):R16PubMed
34.
Laakso M et al (2006) Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 12(14 Pt 1):4185–4191PubMed
35.
Rodriguez-Pinilla SM et al (2007) Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol 60(9):1006–1012PubMed
36.
Carey LA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama 295(21):2492–2502PubMed
37.
Livasy CA et al (2007) Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38(2):197–204PubMed
38.
Rodriguez-Pinilla SM et al (2007) Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 20(4):474–481PubMed
39.
Rodriguez-Pinilla SM et al (2007) Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol 31(4):501–508PubMed
40.
Pinilla SM et al (2006) Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 99(1):85–90PubMed
41.
Matos I et al (2005) p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447(4):688–694PubMed
42.
Paredes J et al (2007) P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 450(1):73–80PubMed
43.
Carey LA et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334PubMed
44.
Livasy CA et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19(2):264–271PubMed
45.
Kim MJ et al (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37(9):1217–1226PubMed
46.
Laakso M et al (2005) Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 18(10):1321–1328PubMed
47.
Li H et al (2007) Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 67(2):501–510PubMed
48.
Lakhani SR et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11(14):5175–5180PubMed
49.
Foulkes WD et al (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64(3):830–835PubMed
50.
Banerjee S et al (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59:729–735PubMed
51.
Fulford LG et al (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9(1):R4PubMed
52.
Jones C et al (2004) Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 10(18):5988–5997PubMed
53.
Potemski P et al (2005) Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 69(6):478–485PubMed
54.
Malzahn K et al (1998) Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 433(2):119–129PubMed
55.
Gusterson BA et al (2005) Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 7:143–148PubMed
56.
Dairkee SH et al (1987) Monoclonal marker that predicts early recurrence of breast cancer. Lancet 1:514PubMed
57.
Tischkowitz M et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7(1):134PubMed
58.
Tan DS et al (2007) Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat [Epub ahead of print]
59.
Rakha EA et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208(4):495–506PubMed
60.
Kusinska R et al (2005) Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma—relation with grade, stage, estrogen receptor and HER2. Pol J Pathol 56(3):107–110PubMed
61.
Rakha EA et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149–3156PubMed
62.
Ribeiro-Silva A et al (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47(5):458–466PubMed
63.
Fulford LG et al (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49(1):22–34PubMed
64.
Jones C et al (2001) CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 85(3):422–427PubMed
65.
Reis-Filho JS et al (2006) Metaplastic breast carcinomas are basal-like tumours. Histopathology 49(1):10–21PubMed
66.
Bankfalvi A et al (2004) Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases. Mod Pathol 17(9):1051–1061PubMed
67.
van de Rijn M et al (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161(6):1991–1996PubMed
68.
Tang P et al (2006) Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Ann Clin Lab Sci 36(1):16–22PubMed
69.
Bryan BB, Schnitt SJ, Collins LC (2006) Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19:617–621PubMed
70.
Tot T (2000) The cytokeratin profile of medullary carcinoma of the breast. Histopathology 37(2):175–181PubMed
71.
Stingl J, Caldas C (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7:791–799PubMed
72.
Moll R (1998) Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem 31:205–262PubMed
73.
Bocker W et al (2002) Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82(6):737–746PubMed
74.
Charafe-Jauffret E et al (2007) Moesin expression is a marker of basal breast carcinomas. Int J Cancer 121(8):1779–1785PubMed
75.
Rodriguez-Pinilla SM et al (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12(5):1533–1539PubMed
76.
Pinilla SM et al (2006) Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 99:85–90PubMed
77.
Reis-Filho JS et al (2003) Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 11(1):1–8PubMed
78.
Leibl S et al (2005) Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 29(3):347–353PubMed
79.
Dent R et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15):4429–4434PubMed
80.
Kreike B et al (2007) Gene expression profiling and histopathological characterization of triple negative/basal-like breast carcinomas. Breast Cancer Res 9(5):R65PubMed
81.
Rakha EA et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109(1):25–32PubMed
82.
Bidard FC et al (2007) Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 ‘triple-negative’ breast cancers. Ann Oncol 18(7):1285–1286PubMed
83.
Rakha EA et al (2007) Are triple negative tumours and basal-like breast cancer synonymous? Breast Cancer Res 9(6):R80
84.
Rouzier R et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678–5685PubMed
85.
Tan DS et al (2007) Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat [Epub ahead of print]
86.
Rody A et al (2007) The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 16(3):235–240PubMed
87.
Abd El-Rehim DM et al (2004) Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 203(2):661–671PubMed
88.
Rhodes A et al (2000) Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 53(2):125–130PubMed
89.
Wolff AC et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145PubMed
90.
West M et al (2001) Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98(20):11462–11467PubMed
91.
Yang XR et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16(3):439–443PubMed
92.
Calza S et al (2006) Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 8(4):R34PubMed
93.
Jacquemier J et al (2005) Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 207(3):260–268PubMed
94.
Bertucci F et al (2006) Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66(9):4636–4644PubMed
95.
Rodriguez-Pinilla SM et al (2007) Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. Am J Surg Pathol 31(4):501–508PubMed
96.
Tsuda H et al (2000) Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 24(2):197–202PubMed
97.
Seewaldt VL, Scott V (2007) Images in clinical medicine. Rapid progression of basal-type breast cancer. N Engl J Med 356(13):e12PubMed
98.
Collett K et al (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14(5):1108–1112PubMed
99.
Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25(43):5846–5853PubMed
100.
Turner NC et al (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14):2126–2132PubMed
101.
Palacios J et al (2003) Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9(10 Pt 1):3606–3614PubMed
102.
Arnes JB et al (2005) Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11(11):4003–4011PubMed
103.
Lakhani SR et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318PubMed
104.
Foulkes WD et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95(19):1482–1485PubMed
105.
Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4(10):814–819PubMed
106.
Stoppa-Lyonnet D et al (2000) Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 18(24):4053–4059PubMed
107.
Haffty BG et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657PubMed
108.
Perreard L et al (2006) Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8(2):R23PubMed
109.
Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312(25):1604–1608PubMedCrossRef
110.
Pedersen L et al (1995) Medullary carcinoma of the breast. Prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer 31A(13–14):2289–2295PubMed
111.
Rapin V et al (1988) Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 61(12):2503–2510PubMed
112.
Eichhorn JH (2004) Medullary carcinoma, provocative now as then. Semin Diagn Pathol 21(1):65–73PubMed
113.
Patanaphan V, Salazar OM, Risco R (1988) Breast cancer: metastatic patterns and their prognosis. South Med J 81(9):1109–1112PubMed
114.
Hicks DG et al (2006) Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30(9):1097–1104PubMed
115.
Gaedcke J et al (2007) Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. Mod Pathol 20(8):864–870PubMed
116.
Palmieri D et al (2006) Brain metastases of breast cancer. Breast Dis 26:139–147PubMed
117.
Grupka NL et al (2004) Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status. Arch Pathol Lab Med 128(9):974–979PubMed
118.
Eusebi V et al (1987) Adenomyoepithelioma of the breast with a distinctive type of apocrine adenosis. Histopathology 11(3):305–315PubMed
119.
Foschini MP, Eusebi V (1998) Carcinomas of the breast showing myoepithelial cell differentiation. A review of the literature. Virchows Arch 432(4):303–310PubMed
120.
Lakhani SR et al (1995) Malignant myoepithelioma (myoepithelial carcinoma) of the breast: a detailed cytokeratin study. J Clin Pathol 48(2):164–167PubMed
121.
Thorner PS et al (1986) Malignant myoepithelioma of the breast. An immunohistochemical study by light and electron microscopy. Cancer 57(4):745–750PubMed
122.
Pia-Foschini M et al (2003) Salivary gland-like tumours of the breast: surgical and molecular pathology. J Clin Pathol 56(7):497–506PubMed
123.
Kinkor Z et al (2004) Matrix-producing breast carcinoma with myoepithelial differentiation—description of 11 cases and review of literature aimed at histogenesis and differential diagnosis. Ceska Gynekol 69(3):229–236PubMed
124.
Stingl J et al (2001) Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue. Breast Cancer Res Treat 67(2):93–109PubMed
125.
Birnbaum D et al (2004) Basal and luminal breast cancers: basic or luminous? (review). Int J Oncol 25(2):249–258PubMed
126.
Dontu G et al (2003) Stem cells in normal breast development and breast cancer. Cell Prolif 36(Suppl 1):59–72PubMed
127.
Behbod F, Rosen JM (2005) Will cancer stem cells provide new therapeutic targets? Carcinogenesis 26(4):703–711PubMed
128.
Reis-Filho JS (2005) Re: Korsching et al. The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 206:451–457. J Pathol (2005) 207(3):367–369; author reply 370–371
129.
Foulkes WD (2004) BRCA1 functions as a breast stem cell regulator. J Med Genet 41(1):1–5PubMed
130.
Hosey AM et al (2007) Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 99(22):1683–1694PubMed
131.
McCarthy A et al (2007) A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol 211(4):389–398PubMed
132.
Gould VE (1986) Histogenesis and differentiation: a re-evaluation of these concepts as criteria for the classification of tumors. Hum Pathol 17(3):212–215PubMed
133.
Brown DC et al (1987) Cytokeratin expression in smooth muscle and smooth muscle tumours. Histopathology 11(5):477–486PubMed
134.
Simpson PT et al (2005) Molecular evolution of breast cancer. J Pathol 205(2):248–254PubMed
Metadata
Title
Patho-biological aspects of basal-like breast cancer
Authors
Emad A. Rakha
Maysa E. El-Sayed
Jorge Reis-Filho
Ian O. Ellis
Publication date
01-02-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-9952-1

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue

Letter to the Editor

Life-threatening interstitial lung disease associated with trastuzumab: case report

Clinical Trial

PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer

Epidemiology

Receipt of adjuvant systemic therapy among patients with high-risk breast cancer detected by mammography screening

Epidemiology

Multiparity and the risk of premenopausal breast cancer: different effects across ethnic groups in Singapore

Epidemiology

The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study

Letter to the Editor

BRCA1 2080insA mutation in familial breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits